Ascendis Pharma A/S - American Depositary Shares — Dividend History & Yield (NASDAQ:ASND) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Dividends per share —————— — Dividend yield % —————— — Payout ratio % —————— —

News

FDA approves Ascendis’ once-weekly achondroplasia treatment

Ascendis Pharma schedules annual meeting and releases 2025 reports

RBC Capital reiterates Ascendis Pharma stock rating on Yorvipath momentum

Cantor Fitzgerald raises Ascendis Pharma stock price target to $300 on CNP franchise outlook

Stifel raises Ascendis Pharma stock price target to $325 on Yorvipath growth

Baird maintains BioMarin stock rating amid competitor’s positive trial data

BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

Earnings call transcript: Ascendis Pharma Q4 2025 misses EPS expectations

Ascendis Pharma misses Q4 revenue estimates despite strong YORVIPATH sales

Ascendis Pharma AS earnings missed by €0.40, revenue fell short of estimates

ASG: Difficult To Make A Case For Buying This Underperforming Fund Today (NYSE:ASG)